See more : Avance Gas Holding Ltd (AVACF) Income Statement Analysis – Financial Results
Complete financial analysis of Centogene N.V. (CNTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Centogene N.V., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Toyobo Co., Ltd. (TYOBY) Income Statement Analysis – Financial Results
- Technocraft Industries (India) Limited (TIIL.NS) Income Statement Analysis – Financial Results
- IndiaMART InterMESH Limited (INDIAMART.BO) Income Statement Analysis – Financial Results
- China Literature Limited (CHLLF) Income Statement Analysis – Financial Results
- Metsä Board Oyj (0O7A.IL) Income Statement Analysis – Financial Results
Centogene N.V. (CNTG)
About Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.54M | 47.47M | 189.92M | 128.38M | 48.78M | 40.48M | 31.69M | 27.67M |
| Cost of Revenue | 35.93M | 27.71M | 161.77M | 86.38M | 26.01M | 19.94M | 14.94M | 12.86M |
| Gross Profit | 11.61M | 19.76M | 28.16M | 42.00M | 22.78M | 20.54M | 16.75M | 14.81M |
| Gross Profit Ratio | 24.42% | 41.63% | 14.83% | 32.72% | 46.69% | 50.74% | 52.86% | 53.54% |
| Research & Development | 10.17M | 17.49M | 19.30M | 14.94M | 9.59M | 6.30M | 6.40M | 5.89M |
| General & Administrative | 29.17M | 29.21M | 44.79M | 37.67M | 23.16M | 18.61M | 9.50M | 8.89M |
| Selling & Marketing | 12.56M | 9.92M | 9.86M | 7.58M | 9.25M | 7.47M | 5.90M | 5.36M |
| SG&A | 41.68M | 39.13M | 54.65M | 45.25M | 32.41M | 26.08M | 15.40M | 14.25M |
| Other Expenses | 1.91M | -340.00K | -970.00K | -2.22M | 109.00K | -2.14M | 0.00 | 290.51K |
| Operating Expenses | 49.93M | 56.28M | 72.98M | 57.96M | 42.11M | 30.25M | 21.28M | 19.21M |
| Cost & Expenses | 85.86M | 83.99M | 234.74M | 144.34M | 68.12M | 50.19M | 36.22M | 32.07M |
| Interest Income | 209.00K | 3.00K | 3.00K | 6.00K | 16.00K | 33.00K | 14.00K | 26.00K |
| Interest Expense | 8.20M | 3.57M | 851.00K | 1.04M | 2.03M | 1.08M | 1.02M | 829.00K |
| Depreciation & Amortization | 7.45M | 10.19M | 20.77M | 14.09M | 6.56M | 5.34M | 3.04M | 2.19M |
| EBITDA | -30.87M | -26.00M | -41.03M | -50.12M | -12.74M | -5.40M | -1.29M | -2.94M |
| EBITDA Ratio | -64.93% | -54.77% | -12.39% | -0.64% | -26.12% | -11.12% | -4.04% | -8.28% |
| Operating Income | -38.32M | -36.52M | -44.82M | -15.96M | -19.34M | -10.61M | -4.46M | -4.94M |
| Operating Income Ratio | -80.61% | -76.92% | -23.60% | -12.43% | -39.64% | -26.20% | -14.06% | -17.84% |
| Total Other Income/Expenses | 3.08M | -1.82M | -4.22M | 32.63M | -1.36M | -1.94M | -1.01M | -741.00K |
| Income Before Tax | -34.23M | -38.60M | -46.88M | -21.10M | -20.70M | -11.65M | -5.46M | -5.77M |
| Income Before Tax Ratio | -71.99% | -81.30% | -24.68% | -16.43% | -42.43% | -28.78% | -17.24% | -20.84% |
| Income Tax Expense | 281.12K | 107.00K | -24.00K | 281.00K | 158.00K | -310.00K | 14.00K | -408.00K |
| Net Income | -34.80M | -38.70M | -46.85M | -21.38M | -20.86M | -11.34M | -5.48M | -5.36M |
| Net Income Ratio | -73.21% | -81.53% | -24.67% | -16.65% | -42.75% | -28.01% | -17.28% | -19.37% |
| EPS | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| EPS Diluted | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| Weighted Avg Shares Out | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
| Weighted Avg Shares Out (Dil) | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
CENTOGENE Receives Delisting Notice From Nasdaq
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
Source: https://incomestatements.info
Category: Stock Reports